155 related articles for article (PubMed ID: 11704613)
1. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis.
Casale TB
Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 2):S18-21. PubMed ID: 11704613
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
Okubo K; Ogino S; Nagakura T; Ishikawa T
Allergol Int; 2006 Dec; 55(4):379-86. PubMed ID: 17130680
[TBL] [Abstract][Full Text] [Related]
3. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
5. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.
Ogino S; Nagakura T; Okubo K; Sato N; Takahashi M; Ishikawa T
Int Arch Allergy Immunol; 2009; 149(3):239-45. PubMed ID: 19218816
[TBL] [Abstract][Full Text] [Related]
6. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.
Adelroth E; Rak S; Haahtela T; Aasand G; Rosenhall L; Zetterstrom O; Byrne A; Champain K; Thirlwell J; Cioppa GD; Sandström T
J Allergy Clin Immunol; 2000 Aug; 106(2):253-9. PubMed ID: 10932067
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
Dodig S; Richter D; Cepelak I; Benko B
Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
Casale TB; Busse WW; Kline JN; Ballas ZK; Moss MH; Townley RG; Mokhtarani M; Seyfert-Margolis V; Asare A; Bateman K; Deniz Y;
J Allergy Clin Immunol; 2006 Jan; 117(1):134-40. PubMed ID: 16387596
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
10. Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update.
Okubo K; Nagakura T
Allergol Int; 2008 Sep; 57(3):205-9. PubMed ID: 18724074
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
[TBL] [Abstract][Full Text] [Related]
12. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
13. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
14. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
16. [Seasonal variations of serum-IgE and potential impact on dose-calculation of omalizumab (rhuMab-E25, anti-IgE)].
Beeh KM; Beier J; Buhl R
Pneumologie; 2004 Aug; 58(8):546-51. PubMed ID: 15293167
[TBL] [Abstract][Full Text] [Related]
17. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.
Casale TB;
Drugs Today (Barc); 2004 Apr; 40(4):367-76. PubMed ID: 15190389
[TBL] [Abstract][Full Text] [Related]
19. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
Verbruggen K; Van Cauwenberge P; Bachert C
Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease.
Berger WE
Ann Allergy Asthma Immunol; 2002 Feb; 88(2):152-60; quiz 161-2, 208. PubMed ID: 11868919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]